2-peptide research blend in one vial: Tesamorelin + Ipamorelin. GH-secretagogue blend — Tesamorelin (the only FDA-approved ingredient across these blends) and Ipamorelin, typically 10:3.
Also known as: Tesa/Ipa
A blend has one whole-vial purity, but the number that decides what you're holding is the net content of each component — an HPLC run resolves a separate peak for each. So we verify Tesamorelin + Ipamorelin component by component. Each links to its own compound page, where its full independent testing lives.
| Component | Typical mg | Role in the blend | Verified purity | |
|---|---|---|---|---|
| Tesamorelin | 10 mg | Raises GH/IGF-1; targets visceral fat (FDA-approved GHRH analog) | 99.4% · 462 tests | View testing → |
| Ipamorelin | 3 mg | Triggers a selective GH pulse | 99.7% · 389 tests | View testing → |
Composition varies by vendor. The components above are consistent across shops, but the milligrams can differ — always dose by the individual component amounts printed on your vial, never by a generic “blend dose.”
A blend is the single hardest product to trust — the whole-vial purity tells you the material is clean, but not whether every peptide is present in the right amount. Two questions decide that, and both are answerable in a lab.
Mass spec (or a clean HPLC peak per compound) confirms each peptide is in the vial — not one short, not a cheaper substitute standing in for the expensive one.
Tested milligrams vs. labelled milligrams, per component. This is where blends fail quietly — one component underdosed to pad margin while the vial still “contains” everything.
Tests run on a Tesamorelin + Ipamorelin vial as sold — broken down per component. This is the data no shop and no competitor publishes.
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| Ipamorelin | — | 5.31 mg | ✓ present | — |
| Tesamorelin | — | 10.54 mg | ✓ present | — |
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| Ipamorelin | 6 mg | 8.37 mg | ✓ present | Over (+39.5%) |
| Tesamorelin | 11 mg | 13.84 mg | ✓ present | Over (+25.8%) |
| Component | Labelled | Net content (tested) | Identity (LC-MS) | Vs. label |
|---|---|---|---|---|
| Ipamorelin | 5 mg | 5.13 mg | ✓ present | Within (+2.6%) |
| Tesamorelin | 5 mg | 5.19 mg | ✓ present | Within (+3.8%) |
Until more Tesamorelin + Ipamorelin vials are tested, the strongest signal is how each component performs in single-compound testing across the shops we track. Tap any card for its full data.
Tesamorelin + Ipamorelin is a two-peptide growth-hormone-secretagogue blend combining Tesamorelin and Ipamorelin in one vial, sold for research use only. It stands apart from the other GH blends for one reason: Tesamorelin is the only component across any of these blends that is actually FDA-approved — so the per-component lab data above matters as much for confirming which GHRH analog you have as for confirming how much.
Tesamorelin + Ipamorelin is a two-peptide blend pairing a growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone secretagogue, most commonly sold as 10 mg tesamorelin + 3 mg ipamorelin in a single vial (a fixed 10:3 ratio). Tesamorelin is a stabilised GHRH analog — the active ingredient in the FDA-approved drug Egrifta — that raises endogenous GH and IGF-1 output; Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that triggers a clean GH pulse without meaningfully raising cortisol or prolactin. The blend is oriented toward visceral-fat and body-recomposition research.
The two components, and what each contributes:
| Component | Class & attributes | Role in the blend |
|---|---|---|
| Tesamorelin | Stabilised GHRH analog (GRF 1-44 analog), FDA-approved as Egrifta; DPP-4-resistant | Raises GH/IGF-1; targets visceral fat |
| Ipamorelin | Selective GH secretagogue, ghrelin/GHS-R agonist, pentapeptide | Triggers a selective GH pulse |
This pairing belongs to the growth-hormone-secretagogue family and is discussed alongside its comparators in Ipamorelin vs sermorelin vs tesamorelin.
Tesamorelin and Ipamorelin are combined because they raise growth hormone through two complementary mechanisms. Tesamorelin, as a GHRH analog, increases the amount of GH the pituitary produces and sustains higher IGF-1; Ipamorelin, as a selective ghrelin-receptor agonist, triggers a distinct GH pulse with minimal effect on cortisol or prolactin. Pairing a GHRH analog with a secretagogue produces a larger, more physiological pulse than either alone. The distinction from the more common CJC-1295 pairing is that Tesamorelin is a more potent, visceral-fat-targeted GHRH analog with actual regulatory approval behind it. Mechanism detail is in the Ipamorelin science guide and the Tesamorelin science guide.
No controlled clinical trial of the Tesamorelin + Ipamorelin combination has been published as of July 2026 — but Tesamorelin carries the strongest human evidence of any ingredient in any of these blends. It is FDA-approved (Egrifta) for reducing excess visceral fat in HIV-associated lipodystrophy, on the strength of two double-blind placebo-controlled Phase 3 trials beginning with Falutz et al., NEJM 2007 and a pooled Phase 3 analysis, with visceral adipose tissue reductions of roughly 15% or more over six months (evidence level: human RCT / FDA-approved, HIV-lipodystrophy population). Ipamorelin was characterised as the first selective GH secretagogue in preclinical and early human work (evidence level: preclinical and early clinical). Two honest limits: the visceral-fat data is for Tesamorelin monotherapy in a specific HIV population, not the blend and not the general public; and no trial has tested whether adding Ipamorelin improves on Tesamorelin alone.
Both are GHRH-analog + Ipamorelin blends, so the real question is Tesamorelin versus CJC-1295 as the GHRH component. Tesamorelin is the more potent, visceral-fat-specific analog with FDA approval and RCT data; CJC-1295 (without DAC) is the cheaper, more common research analog with human pharmacodynamic data but no approval. Tesamorelin's evidence is stronger but comes from a narrow clinical population; CJC-1295 is the default in general GH-recomposition research. Neither combination has been tested as a blend in a controlled trial.
| Blend | GHRH-analog component | Evidence & regulatory status | Typical focus |
|---|---|---|---|
| Tesamorelin + Ipamorelin | Tesamorelin (stabilised GRF) | FDA-approved (Egrifta); Phase 3 RCT data | Visceral fat |
| CJC-1295 + Ipamorelin | CJC-1295 (no-DAC / Mod GRF) | Not approved; human GH/IGF-1 PK data | General GH / recomposition |
A Tesamorelin + Ipamorelin vial is worth verifying because two things can be wrong that a single number won't reveal: whether the GHRH component is really the (more expensive) tesamorelin, and whether each peptide is at label strength. A certificate reports one whole-vial HPLC purity — how clean the material is — but that can read above 99% while a component is underdosed or substituted, so the verifiable signals are per-component identity (mass spectrometry confirming both peptides by molecular weight) and net content (tested milligrams versus label, for each). Because tesamorelin is costlier than the cheaper GHRH analogs it can be swapped for, identity confirmation carries real weight here. Peptigrity's independent lab-test database publishes both dimensions; learn to read them in how to read peptide lab test results.
Peptigrity verifies a Tesamorelin + Ipamorelin vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming both peptides are present and are the peptides claimed, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for tesamorelin and ipamorelin individually), and endotoxin testing. Peptigrity purchases vials anonymously at standard pricing and publishes the unedited certificate; the methodology and shop trust-score weighting are documented in how we calculate trust scores. The broader process is in the how to test peptides hub and the testing labs directory. For sourcing the secretagogue component, see where to buy Ipamorelin.
In a fixed 10:3 Tesamorelin + Ipamorelin vial you set the dose of one peptide and the other follows the ratio, since the two are present in a fixed proportion. A common research-planning approach reconstitutes the 13 mg vial (10 mg tesamorelin + 3 mg ipamorelin) and draws a single dose, often timed before sleep to align with the body's overnight GH pulse — the same nightly-timing logic used for tesamorelin monotherapy. The blend calculator converts the two amounts into a reconstitution and draw, and the tesamorelin calculator covers the tesamorelin component specifically. No clinical dosing protocol exists for the combination; the approved tesamorelin dose (2 mg/day) is for HIV-associated lipodystrophy under medical supervision, not a self-administration guide for the blend.
The regulatory picture is split. Tesamorelin is FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-associated lipodystrophy — the only approved indication — but the research-grade tesamorelin sold in blends is not an approved product and is supplied for research use only. Ipamorelin is not approved for any indication. The FDA compounding-category status for these GH peptides has been in flux through 2025–2026 and should be re-verified against the current FDA bulk-substances determinations before relying on it. Both Tesamorelin and Ipamorelin are prohibited by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, and related substances), so the blend is banned in competitive sport. Buyers are responsible for confirming local import rules for research chemicals in their jurisdiction.
In a blend you can only set the dose of one component — the rest follow the fixed ratio. Our calculator does that math so you don't underdose the peptide you actually care about.
Enter each component's milligrams and your BAC water — get per-component units for one syringe draw.
Open the blend calculator →How much bacteriostatic water, mixing without shaking, storage, and shelf life once mixed.
Read the reconstitution guide →No — they share the Ipamorelin component but use different GHRH analogs. Tesamorelin is a more potent, visceral-fat-targeted analog that is FDA-approved (Egrifta) and backed by Phase 3 trials; CJC-1295 (without DAC) is a cheaper, more common research analog with human pharmacodynamic data but no approval. The Tesamorelin blend has stronger evidence behind its GHRH component, though from a narrow clinical population, while the CJC-1295 blend is the general-purpose default.
Because the two raise growth hormone through complementary mechanisms. Tesamorelin, a GHRH analog, increases GH and IGF-1 output and targets visceral fat; Ipamorelin, a selective secretagogue, adds a GH pulse without significantly affecting cortisol or prolactin. Together they aim for a larger, cleaner pulse than either alone — although no controlled trial has tested the combination, and the visceral-fat evidence belongs to tesamorelin monotherapy.
Tesamorelin is FDA-approved as Egrifta for one specific use: reducing excess abdominal fat in HIV-associated lipodystrophy. It is not approved for general weight loss, body recomposition, or anti-aging, and the research-grade tesamorelin sold in blends is not an approved product — it is supplied for research use only. So the compound has real regulatory approval, but not for the uses the blend is typically associated with.
Yes, using two measurements. A lab reports a single whole-vial HPLC purity plus the net content of each peptide separately, with mass-spec identity confirmation. Identity matters here because tesamorelin is more expensive than the GHRH analogs it can be substituted with, so confirming the vial actually contains tesamorelin — and both peptides at label strength — is the point of testing.
No. Peptigrity is an independent review platform, not a medical authority, and the blend is not an approved product. The approved tesamorelin dose applies to a specific HIV population under medical supervision, not to self-administration of a blend, and no trial has established a dose for the combination. Anyone considering use of investigational compounds should consult a licensed physician.